ENTA - Enanta potential COVID drug shows safety in healthy people in early-stage trial

• Enanta Pharmaceuticals ( NASDAQ: ENTA ) said its potential oral COVID-19 therapy EDP-235 was seen to be safe and tolerable in a phase 1 study.
• The company added that data from the trial supports advancing EDP-235 into a phase 2 study using once-daily dosing, without ritonavir.
• "We are very pleased with the encouraging results from our Phase 1 study of EDP-235 showing that it was generally safe and well-tolerated up to a once-daily dose of 400mg, which provided plasma drug levels that were 6-fold and 12-fold over the plasma protein adjusted EC for the Alpha variant and the Delta variant, respectively," said Enanta President and CEO Jay Luly.
• In the phase 1 study, the company evaluated multiple doses of EDP-235 against placebo.
• The company added that the majority of adverse events (AEs) were mild, with headache and gastrointestinal related symptoms (e.g. nausea, abdominal discomfort) being the most frequently reported AEs during the multiple ascending doses phase.

For further details see: